Twist Bioscience (TWST) Net Cash Flow (2017 - 2026)

Twist Bioscience has disclosed Net Cash Flow across 10 years of filings, most recently posting -$26.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 132.94% year-over-year to -$26.1 million; the TTM figure through Mar 2026 stood at -$88.2 million (down 164.08% YoY), while the FY2025 annual figure was -$43.8 million, up 27.25% from the prior year.
• Net Cash Flow improved to -$26.1 million in Q1 2026, from -$34.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for TWST reached as high as $216.0 million in Q1 2022 and fell as low as -$61.4 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$13.0 million (2024), against an average of -$4.0 million.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 327.75% — and 2024, when it tumbled 1324.52%.
• A 5-year view of Net Cash Flow shows it stood at -$61.4 million in 2022, then soared by 66.99% to -$20.3 million in 2023, then surged by 75.25% to -$5.0 million in 2024, then sank by 586.24% to -$34.4 million in 2025, then increased by 24.16% to -$26.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$26.1 million, -$34.4 million, and -$18.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.